• Led a team responsible for preclinical studies and immune assays as the non-clinical lead for the RNA vaccine development program.• Led several discovery initiatives for novel vaccine platforms within the research organization in the capacity of non-clinical lead.• Provided strategic support to senior management regarding emerging knowledge in the RNA vaccine space.• Contributed to due diligence teams exploring new assets of strategic importance for the organization.• Identified emerging trends in immunology and implemented state-of-the-art immuno-technologies (OMICS, transgenic animal models, etc.) to ensure that research efforts remain at the forefront of innovation.• Established and maintained strong relationships with key stakeholders across J&J business units and external CROs.• Hired, led, mentored, and inspired a team of professionals while supporting their professional development.• Developed and delivered clear and concise communications (publications, presentations, patents, and reports) to keep stakeholders informed about Research strategy, program status, and outcomes.• Disease targets: RSV, Ebola and SARS-CoV-2

• Successfully obtained an EU grant for €185K to conduct research on the mechanism of action (MoA) of mucosal adjuvants.• Designed and implemented an in vitro lung model to examine the communication between structural cells and immune cells.• Developed a comprehensive panel for immunophenotyping cells, enabling transcriptomic profiling in the lung compartment of pre-clinical murine models.• Formed collaborations with academic partners to advance the development of a conjugated protein vaccine.• Disease targets: Malaria

• Formulated a conjugated protein vaccine utilizing click-chemistry against various malaria antigens.• Implemented procedures for the expression, isolation, refolding, and purification of recombinant antigens from bacteria.• Developed crucial components of automated downstream processes with large-scale chromatographic units in recombinant protein production.• Established protocols for generating conjugate vaccines with CRM197 using click chemistry.• Oversaw collaborations with academic partners and delivered presentations on research findings to key stakeholders.• Disease targets: Malaria

• Developed vaccinia based viral vector (MVA) vaccines against malaria and HIV and designed in vivo studies to investigate its immunogenicity in mice and rabbits.• Designed and generated trimeric gp120 (HIV) protein vaccine from mammalian cells.• Developed new ligand binding assays to characterize bnAbs against HIV generated by vaccines.• Developed in vitro cell based assays to study innate immune responses generated by vaccines.• Established collaborations with US academic partner to generate new transgenic parasites for challenge studies.• Authored several publications and a patent.